Company intelligence / Profile preview

TuHURA Biosciences, Inc.

Tampa, Florida, United Statestuhurabio.com ↗

Ownership: Public · HURA
Employees: ~19
Development stage: Phase 3

Overview

TuHURA’s lead candidate IFx‑2.0 is a first-in-class innate immune response agonist designed to overcome primary resistance to checkpoint inhibitors. A single randomized placebo-controlled Phase 3 registration trial as adjunctive therapy with Keytruda® in advanced/metastatic Merkel Cell Carcinoma is set to begin in early/mid‑2025. The company also advances bi-specific ADCs/PDCs targeting MDSCs and plans expansion into additional indications such as aggressive lymphomas. Early clinical data have not yet been published from the new pipeline post-merger.[1][6]

Therapeutic areas: Oncology
Modalities: Personalized innate immune agonists (e.g., IFx technology)Bi-specific antibody drug conjugates (ADCs)Peptide drug conjugates (PDCs)Cancer vaccinesmRNA-based therapies[1][2][5][7]
Industry: Biotech

Drug pipeline

12 assets

IFx-Hu2.0

11 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships announced yet but company states intent to seek collaborations/licensing deals with large pharmaceutical or biotech companies.[2]Has entered exclusivity/right-of-first-offer agreements regarding Kineta's KVA12123 asset.[10]

Financials

Market cap: $129.3M
Total revenue: $0
Enterprise value: $128.7M

Beyond the preview

Go deeper on TuHURA Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TuHURA Biosciences, Inc..

Explore the full profile